1205543-29-8

Basic information

• Product Name: [(S)-3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-1-hydroxymethyl-propyl]-carbamic acid benzyl ester
• Synonyms: [(S)-3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-1-hydroxymethyl-propyl]-carbamic acid benzyl ester
• CAS NO: 1205543-29-8
• Molecular Weight: 348.442
• Mol File: 1205543-29-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [(S)-3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-1-hydroxymethyl-propyl]-carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(S)-3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-1-hydroxymethyl-propyl]-carbamic acid benzyl ester(1205543-29-8)
• EPA Substance Registry System: [(S)-3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-1-hydroxymethyl-propyl]-carbamic acid benzyl ester(1205543-29-8)

Safety Data

• Hazardous Substances Data: 1205543-29-8(Hazardous Substances Data)

Upstream product

• 118219-23-1 [(1S)-3-hydroxy-1-(hydroxymethyl)propyl]carbamic acid phenylmethyl ester 
• 607376-67-0 (S)-2,2-dimethyl-4-(2-oxo-ethyl)-oxazolidine-3-carboxylic acid benzyl ester 
• 607376-66-9 2-[(4S)-(3-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-y)]ethanol 
• 1205543-28-7 (S)-4-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-ethyl]-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 

Downstream Products

• 1282532-03-9 (3S,6S)-3-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-ethyl]-6-methyl-5-oxo-hexahydro-oxazolo[3,2-a]pyrazine-7-carboxylic acid benzyl ester 
• 1282532-01-7 (3S,6S,8aS)-3-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-ethyl]-6-methyl-5-oxo-hexahydro-oxazolo[3,2-a]pyrazine-7-carboxylic acid (3,4-dichloro-phenyl)-amide 
• 1282532-02-8 (3S,6S,8aR)-3-[2-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-ethyl]-6-methyl-5-oxo-hexahydro-oxazolo[3,2-a]pyrazine-7-carboxylic acid (3,4-dichloro-phenyl)-amide 

Relevant articles and documents

BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS

The invention is concerned with novel bicyclic compounds of formula (I), wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compound

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.